EVA MARÍA
CIRUELOS GIL
Profesora asociada de Ciencias de la Salud
Fondazione IRCCS Istituto Nazionale dei Tumori
Milán, ItaliaPublicaciones en colaboración con investigadores/as de Fondazione IRCCS Istituto Nazionale dei Tumori (9)
2023
-
Spatial predictors of immunotherapy response in triple-negative breast cancer
Nature, Vol. 621, Núm. 7980, pp. 868-876
2022
2021
-
Genomic and transcriptomic analyses of breast cancer primaries and matched metastases in Aurora, the breast international group (Big) molecular screening initiative
Cancer Discovery, Vol. 11, Núm. 11, pp. 2796-2811
2020
-
Immune system and angiogenesis-related potential surrogate biomarkers of response to everolimus-based treatment in hormone receptor-positive breast cancer: an exploratory study
Breast Cancer Research and Treatment, Vol. 184, Núm. 2, pp. 421-431
2019
-
Survival outcomes of the NeoALTTO study (BIG 1–06): updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancer
European Journal of Cancer, Vol. 118, pp. 169-177
2016
-
Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors: Primary results of a phase IIIb, open-label, single-arm, expanded-access multicenter trial (BALLET)
Annals of Oncology, Vol. 27, Núm. 9, pp. 1719-1725
2014
-
Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): Follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort
The Lancet Oncology, Vol. 15, Núm. 6, pp. 640-647
2012
-
Pathological complete response rates following different neoadjuvant chemotherapy regimens for Operable Breast Cancer according to ER status, in two parallel, randomized phase II trials with an adaptive study design (ECTO II)
Breast Cancer Research and Treatment, Vol. 132, Núm. 3, pp. 843-851
2010
-
Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort
The Lancet, Vol. 375, Núm. 9712, pp. 377-384